Troubles du Développement
Chapitre C.2
La promotion de la santé et la prévention des maladies nécessitent une action multisectorielle qui renforce les environnements favorables à la santé et oriente les comportements. Au niveau des cantons et des communes, de nombreuses politiques, telles
la protection de la jeunesse, la promotion ...de la santé à l’école, la promotion de la santé et de la sécurité au travail, l’action sociale, le soutien au logement, la promotion de l’intégration, l’aménagement du territoire, la gestion de la mobilité ou la protection
de l’environnement sont des leviers très efficaces pour améliorer l’état de santé de la population.
L’argumentaire «Promouvoir la santé et prévenir les maladies» a pour objectif d’expliquer les enjeux et
d’inciter les personnes actives dans ces divers domaines à intégrer la promotion de la santé dans leurs activités et projets. Cela exige de leur mettre à disposition des informations actuelles et facilement compréhensibles
more
This review examines high-quality research evidence that synthesises the efects of extreme heat on human health in tropical
Africa. Web of Science (WoS) was used to identify research articles on the efects extreme heat, humidity, Wet-bulb Globe
Temperature (WBGT), apparent temperature, wind, Heat ...Index, Humidex, Universal Thermal Climate Index (UTCI), heatwave, high temperature and hot climate on human health, human comfort, heat stress, heat rashes, and heat-related morbidity
and mortality
more
Introducción
Capítulo A.1
The State of the World's Midwifery
To save the lives of mothers and their babies, mitigate complications, and limit the spread of disease, it is critical that recommendations are made on the prevention, treatment, and surveillance of women who are exposed to EVD, acquire EVD during pregnancy or breastfeeding, or survive EVD with ongo...ing pregnancies. These guidelines are the first to provide such recommendations.
more
Vaccines 2021, 9(2), 160; https://doi.org/10.3390/vaccines9020160
1-13 December 2018 | Geneva, Switzerland UNAIDS Programme Coordinating Board Issue date: 23 November 2018
UNAIDS/PCB (43)/18.32
Low- and middle-income countries (LMICs) experience a high disease burden for epilepsy, a chronic neurological condition.The authors evaluate the cost-effectiveness of community health workers (CHWs) to improve adherence to medication for epilepsy in South Africa. They found that utilizing CHWs to i...mprove medication adherence was cost-effective.
more
Review
Drake AL et al. Journal of the International AIDS Society 2019, 22:e25271 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25271/full | https://doi.org/10.1002/jia2.25271
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug... Monitoring. This text was developed in consultation with the WHO Collaborating Centre for International Drug Monitoring and the national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring.
more
J Int Assoc Provid AIDS Care. 2017 ; 16(5): 499–505. doi:10.1177/2325957417709089.
Integrated Management of pregnancy and childbirth
Training Module on Malaria
This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response
to the Sixty-second World Health Assembly’s resolution on prevention and control of multidrug-resistant tuberculosis and e...xtensively drug-resistant tuberculosis.
more
This document provides interim recommendations for the surveillance of Zika virus infection, microcephaly and Guillain-Barré syndrome, in four different contexts and describes reporting requirements to WHO. Transmission refers to vector-borne transmission, unless specified differently. Autochthonou...s infection is considered to be an infection acquired in-country, i.e. among patients with no history of travel during the incubation period or who have travelled exclusively to non-affected areas during the incubation period. This document does not provide guidance on laboratory investigation or vector surveillance.
more